Canine Serum amyloid A antibody and antigen (recombinant protein)
Diagnostic anti-Canine Serum amyloid A antibodies pairs and antigen for animal health (animal Dog/Canine Acute inflammation, infections) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-CAN-Serum-amyloid-A-Ag01 | Recombinant Canine Serum amyloid A protein | 3090 |
GMP-CAN-Serum-amyloid-A-Ab01 | Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-Serum-amyloid-A-Ab02 | Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-Serum-amyloid-A-Ab03 | Anti-Canine Serum amyloid A human monoclonal antibody (mAb) | 1953 |
GMP-CAN-Serum-amyloid-A-Ab04 | Anti-Canine Serum amyloid A human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-CAN-Serum-amyloid-A-Ag01 |
Product Name | Recombinant Canine Serum amyloid A protein |
Target/Biomarker | Canine Serum Amyloid A (SAA) |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine Serum Amyloid A antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in SAA level test of animal Dog/Canine with Acute inflammation, infections. |
Tag | His |
Products description | Recombinant Canine Serum amyloid A protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-Serum-amyloid-A-Ab01, GMP-CAN-Serum-amyloid-A-Ab02 |
Product Name | Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) |
Target/Biomarker | Canine Serum Amyloid A (SAA) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine Serum Amyloid A antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-SAA antibodies in SAA level test of animal Dog/Canine with Acute inflammation, infections. |
Tag | mFc |
Products description | Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-SAA antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-Serum-amyloid-A-Ab03, GMP-CAN-Serum-amyloid-A-Ab04 |
Product Name | Anti-Canine Serum amyloid A human monoclonal antibody (mAb) |
Target/Biomarker | Canine Serum Amyloid A (SAA) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Canine Serum Amyloid A antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-SAA antibodies in SAA level test of animal Dog/Canine with Acute inflammation, infections. |
Tag | hFc |
Products description | Anti-Canine Serum amyloid A human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-SAA antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
GeneMedi’s anti-SAA monoclonal antibodies demonstrate superior performance in immunoassay.
GeneMedi’s monoclonal antibodies for SAA (Serum Amyloid A) offer high sensitivity for detecting SAA in cat, dog, and horse serum. Due to the high sequence homology among these species, the same antibody pairs can be used to develop versatile sandwich immunoassays. As a result, GeneMedi’s anti-SAA antibodies provide a valuable tool for accurately monitoring and diagnosing inflammatory conditions across multiple species.
Figure 1. GeneMedi’s monoclonal antibodies demonstrate high sensitivity and specificity for detecting SAA in both healthy and inflammatory cat plasma samples using a sandwich immunoassay.
A. Calibration curve for GMP-FEL-Serum-amyloid-A-Ag01 in mixed cat plasma in the sandwich immunoassay. The SAA concentration in mixed cat plasma was 145 μg/ml, and the sample was diluted 208 times prior to testing.
B-C. Dilution curves for recombinant cat SAA antigen and plasma samples using the prototype reagents in the sandwich immunoassay. (B) Healthy cat samples (H1, H2), with SAA concentrations of 0.67 μg/ml and 0.45 μg/ml, respectively. Plasma samples were diluted 45 times before testing. The initial concentration of GMP-FEL-Serum-amyloid-A-Ag01 was 65 ng/ml. (C) Postoperative cat samples (P1, P2), with SAA concentrations of 169 μg/ml and 220 μg/ml, respectively. Plasma samples were diluted 200 times before testing. The initial concentration of GMP-FEL-Serum-amyloid-A-Ag01 was 200 ng/ml.
D. SAA concentrations in healthy and postoperative inflammatory cats. Healthy cat samples were pre-diluted 100-3000 times, while inflammatory cat samples were pre-diluted 9000 times prior to testing.
Figure 2. GeneMedi’s anti-SAA monoclonal antibodies enable sensitive detection of SAA in dog, horse, and cat serum using a sandwich immunoassay.
A-B. Dilution curves of recombinant dog (A) and horse (B) SAA antigens in the sandwich immunoassay. GMP-CAN-Serum-amyloid-A-Ab01 was coated and blocked at 37°C for 1 hour, and incubated with GMP-CAN-Serum-amyloid-A-Ag01 and GMP-EQU-Serum-amyloid-A-Ag01 at 37°C for 1 hour.
C. The recommended antibody pairs.
D-E. Comparison of SAA detection results between diseased and healthy individuals in dogs (D) and horses (E) in the sandwich immunoassay. Healthy serum was pre-diluted 50 times, while diseased serum was pre-diluted 1500 times (horse) or 2500 times (dog), with the dilution buffer containing 1% casein and 0.05% Tween 20.
F-H. Testing results of SAA in cat (F), dog (G), and horse (H) serum samples in the sandwich immunoassay. GMP-FEL-Serum-amyloid-A-Ab10 was blocked for 1 hour (blocking solution containing 2.5% sodium caseinate). Dog serum was pre-diluted 2500 times, while cat and horse serum were pre-diluted 1500 times, using a Tris buffer containing 0.01% CHAPS.
Click to get more Data / Case study about the product.
Target/Biomarker information
SAA, or Serum Amyloid A, is a remarkable biomarker that occupies a central position in the immune response of dogs (canines) to inflammatory challenges. This protein is primarily synthesized by hepatocytes in the liver and is swiftly released into the bloodstream in response to various inflammatory signals. Its role as an acute-phase protein is fundamental to the canine immune system's ability to detect and combat inflammation, infection, and tissue damage. Structurally, SAA comprises two primary isoforms in dogs, SAA1 and SAA2, both of which can be elevated during inflammatory conditions. These isoforms play a pivotal role in modulating the host's immune response to pathogens and injuries. SAA acts as a chemoattractant for immune cells, facilitating their migration to the site of infection or inflammation. Additionally, SAA can influence other immune responses, including the production of cytokines and other inflammatory mediators. In dogs, SAA serves as a sensitive and early marker of systemic inflammation. When exposed to inflammatory stimuli, such as infections, tissue damage, or other inflammatory conditions, the liver rapidly increases the synthesis of SAA. Elevated levels of SAA in the bloodstream can be detected within hours of the initial trigger, making it a valuable diagnostic tool for veterinarians.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.